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MeCP2 is a nuclear protein with an affinity for meth-
ylated DNA that can recruit histone deacetylases.
Deficiency or excess ofMeCP2 causes severe neuro-
logical problems, suggesting that the number of
molecules per cell must be precisely regulated.
We quantified MeCP2 in neuronal nuclei and found
that it is nearly as abundant as the histone octamer.
Despite this high abundance, MeCP2 associates
preferentially with methylated regions, and high-
throughput sequencing showed that its genome-
wide binding tracks methyl-CpG density. MeCP2
deficiency results in global changes in neuronal chro-
matin structure, including elevated histone acetyla-
tion and a doubling of histone H1. Neither change
is detectable in glia, where MeCP2 occurs at lower
levels. The mutant brain also shows elevated tran-
scription of repetitive elements. Our data argue that
MeCP2 may not act as a gene-specific transcrip-
tional repressor in neurons, but might instead
dampen transcriptional noise genome-wide in a
DNA methylation-dependent manner.
INTRODUCTION
Mammalian genomes exhibit tissue-specific patterns of DNA
methylation, predominantly at the dinucleotide sequence CpG.
Inmost tissues, thebulkgenomehasa relatively lowCpGdensity,
but is heavily (70%)methylated (Ehrlich et al., 1982). This global
distribution is interrupted by regions of high CpG density, termed
CpG islands (CGIs), which are typically unmethylated and asso-
ciated with gene promoters (Bird et al., 1985). The effects of
methylated and nonmethylated CpGs on chromatin metabolism
are mediated by proteins that are either attracted or repelled
by that modification state. MeCP2 is one of several proteins
that bind methylated DNA in vivo and in vitro and is therefore
a potential interpreter of the DNA methylation pattern (Lewis
et al., 1992).MeCP2 ismost highly expressed in the brain, specif-
ically in neurons (Kishi and Macklis, 2004), where neuronalMoleexpression rises postnatally as the final stages of neurogenesis
are completed (Balmer et al., 2003).
Mutations in the X-linked MECP2 gene are the primary cause
of the autism spectrum disorder Rett syndrome (Amir et al.,
1999). In Rett patients, apparently normal development gives
way to regression after 6–12 months, with loss of acquired skills,
including speech andmobility (Armstrong, 2002). TheMecp2 null
mouse recapitulates several features of Rett syndrome, showing
a late-onset neurodevelopmental phenotype leading to death at
12weeks (Chen et al., 2001; Guy et al., 2001). This link between
MeCP2 and a neurological disorder suggests that brain expres-
sion is of key functional importance. Accordingly, brain-specific
depletion of MeCP2 produced mice that are indistinguishable
from Mecp2 null animals (Chen et al., 2001; Guy et al., 2001).
Furthermore, a mouse model expressing MeCP2 under the Tau
promoter, which is primarily neuron-specific, rescued the null
animals (Luikenhuis et al., 2004). These observations highlight
the importance of MeCP2 function in neurons.
Transfection experiments showed that MeCP2, when re-
cruited to a promoter via a GAL4-binding domain, could repress
transcription and that this repression was in part mediated by
an interaction with histone deacetylase (HDAC)-containing
complexes (Nan et al., 1998). These findings suggested that
MeCP2 is a transcriptional repressor targeted to specific genes
via DNA methylation. While subsequent studies have identified
reproducible gene expression changes between wild-type and
Mecp2 null mouse brains, these are generally rather subtle
(Jordan et al., 2007; Nuber et al., 2005), questioning the view
that MeCP2 acts as a classical transcriptional repressor. In
contrast to the original model, recent studies have proposed
that MeCP2 modulates alternative splicing (Young et al., 2005)
and acts as a transcriptional activator by recruiting the transcrip-
tion factor CREB to specific genes (Chahrour et al., 2008). In
addition, there have been reports that MeCP2 binding to DNA
may not depend on methylation, as studies using in vitro chro-
matin assembly suggested that MeCP2 can bind to both methyl-
ated and nonmethylated DNA and mediate nucleosomal
compaction (Georgel et al., 2003; Nikitina et al., 2007). Support
for this view has come from chromatin immunoprecipitation-
microarray (ChIP-chip) experiments using a neuronal cultured
cell line. The report claimed that MeCP2 does not selectively
bind methylated promoters, but instead is bound at many unme-
thylated promoters and has a similar binding pattern to RNAcular Cell 37, 457–468, February 26, 2010 ª2010 Elsevier Inc. 457
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MeCP2 Affects Neuronal Chromatin Globallypolymerase II (Yasui et al., 2007). These findings call for a
re-evaluation of the conventional view that MeCP2 recruits
HDACs to methylated sites.
To distinguish these alternative hypotheses for MeCP2 func-
tion, we measured its abundance and distribution in the mature
mouse brain. An additional motivation was to explain why
MeCP2 abundance is so critical for its function. For example,
expression of MeCP2 from transgenes in mice only brings about
phenotypic rescue if the level of protein is close to that in wild-
type brain; overexpression by 2-fold is severely detrimental
(Collins et al., 2004; Luikenhuis et al., 2004). These findings are
mirrored in humans, where MECP2 gene duplication events
give rise to developmental delay and mental retardation (Lubs
et al., 1999). We developed a technique to purify neuronal nuclei
from the mature mouse brain and found that the absolute
abundance of MeCP2 approaches the number of nucleosomes
and methyl-CpG (meCpG) moieties in a diploid genome. Consis-
tent with its high abundance, ChIP analysis showed MeCP2 to
be globally distributed and to track the density of meCpG in
the genome. Bisulfite sequencing of the immunoprecipitated
DNA confirmed highly selective binding to methylated DNA
sequences. In the absence of MeCP2, histone H3 acetylation
(H3Ac) levels were globally elevated and histone H1 levels
were doubled, suggesting that MeCP2 alters the global chro-
matin state. These changes were not seen in glia or other tissues
where MeCP2 is much less abundant. We propose that a key
neuron-specific role of MeCP2 is to impact the entire genome,
rather than to act as a gene-specific regulator.
RESULTS
MeCP2 Is Enriched in Neuronal Nuclei and Almost
as Abundant as Nucleosomes
As the correct expression level seems to be crucial to MeCP2
function (Collins et al., 2004; Guy et al., 2001; Luikenhuis et al.,
2004), we wanted to determine the absolute abundance of
MeCP2 in themature brain.We first askedwhen during postnatal
development MeCP2 reaches its maximum level by quantitative
western blotting using mice of different ages (Figure S1A).
MeCP2 was weakly detectable in neonatal brain, but increased
rapidly to reach amaximum at5 weeks of age, after which total
levels remained constant. We decided to use 6- to 8-week-old
mice for all subsequent experiments. Immunofluorescence
data have indicated that MeCP2 is predominantly expressed
in neuronal nuclei, with much less being seen in glia (Kishi
and Macklis, 2004). In order to focus on neurons, a procedure
was developed to sort neuronal from glial nuclei using
fluorescence-activated cell sorting (FACS). The vast majority of
neuronal nuclei are positive for staining by the neuronal nuclear
marker NeuN, whereas glial nuclei are negative (Mullen et al.,
1992). NeuN staining of total brain nuclei gave a bimodal inten-
sity distribution comprising 50% NeuN-positive nuclei (neurons)
and 50% negative nuclei (predominantly glia) (Figure 1A). Stain-
ing of brain nuclei for MeCP2 gave a similar bimodal distribution:
56% high and 44% low MeCP2 staining (Figure 1B), with an
approximately 6-fold difference in staining intensity. Sorting of
nuclei on the basis of the NeuN staining purified a neuronal
population and a predominantly glial population of nuclei458 Molecular Cell 37, 457–468, February 26, 2010 ª2010 Elsevier In(Figure 1C). As expected, NeuN-positive nuclei cosorted with
the high MeCP2-expressing nuclei.
Quantitative western blotting using infrared imaging confirmed
that both NeuN andMeCP2 levels were increased in the neuronal
population and depleted in the predominantly glial population
relative to unsorted brain nuclei (Figure 1D). We detected
approximately 7-fold more MeCP2 in NeuN-positive versus
NeuN-negative populations, similar to the difference in the stain-
ing intensities recorded by FACS (about 6-fold). Quantification of
recombinant MeCP2 against a BSA standard (Figure S1B)
allowed us to determine the absolute abundance of MeCP2 in
unsorted nuclei isolated from mature mouse brain as 6 3 106
molecules per nucleus (Figures 1E andS1C). This result was veri-
fied using an independent MeCP2 antibody (Figure S1D). The
amount of MeCP2 in sorted neuronal nuclei (NeuN-positive)
was 16 3 106 molecules per nucleus, compared with 2 3 106
molecules per nucleus in the predominantly glial nuclear fraction
(Figure 1F). For comparison, the abundance of MeCP2 in liver
nuclei was 0.5 3 106 molecules per nucleus (Figure S1E).
FACS staining suggested there may be some heterogeneity
within the populations, indicating that these average values
may not apply to each cell, as previously suggested (LaSalle
et al., 2001). To relate MeCP2 levels to the core components
of chromatin, we determined the abundance of histone H4 as
643 106 molecules per brain nucleus (Figure S1F), which corre-
sponds to 323 106 nucleosomes in total, or one nucleosome per
165 bp of genomic DNA. The estimated number of meCpGs per
diploid nucleus is 403 106 methylated CpG sites. Therefore, the
number of MeCP2 molecules in the nucleus of a mature neuron
approaches the number of histone octamers and meCpG sites
and may be sufficient to almost ‘‘saturate’’ the genome.
MeCP2 Binds Globally across the Genome
in the Mouse Brain
Previous reports using cultured neurons from embryonic or
immature mice have suggested that MeCP2 binds at discrete
genomic sites, such as at the brain-derived neurotrophic factor
gene locus (Bdnf) (Chen et al., 2003) and at the Dlx5/6 locus
(Horike et al., 2005). AsMeCP2 levels are low in immaturemouse
brain compared to the high abundance later on (Figure S1), the
MeCP2 binding pattern in mature mice was determined. We
used whole brain nuclei for MeCP2 ChIP as approximately
89% of brain MeCP2 is derived from neuronal nuclei. We first
tested the specificity of the 674 MeCP2 antibody (Nan et al.,
1998) using the 234 bp mouse major satellite repeat, a known
MeCP2 binding sequence, as a ChIP probe (Nan et al., 1996).
Despite the MeCP2 antibody displaying relatively low efficiency
(1.7% IP/Input), it was highly specific, exhibiting a 130-fold
enrichment in wild-type compared to Mecp2 null mouse brain
(Figure 2A). We concluded that this degree of specificity was
sufficient for analysis of MeCP2 binding in the genome.
Initially, we examined binding to the mouse Bdnf locus, which
has eight alternative first exons, most of which are located in two
large CGIs, with a large intervening intron. A panel of 22 ChIP
primers was designed across a 39 kb region spanning the
CGIs, and the MeCP2 binding profile was determined in mature
mouse brain using ChIP and quantitative PCR. We observed
significant enrichment across the entire region compared withc.
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Figure 1. The Abundance of MeCP2 in Purified Neuronal Nuclei Approaches that of the Histone Octamer
(A and B) Nuclei were isolated from wild-type whole mouse brain and then FACS-stained for NeuN (A) and MeCP2 (B).
(C) Nuclei sorted for NeuN-negative and NeuN-positive staining cosorted with low-MeCP2- and high-MeCP2-stained nuclei, respectively.
(D) Infrared western blotting for NeuN,MeCP2, and histone H3was performed on unsorted and FACS-sorted nuclei. The graph indicates quantification of western
signals normalized for H3 loading.
(E) The level of MeCP2 in unsorted brain nuclei was quantified against recombinant MeCP2 by infrared western blotting (E). The graph below indicates densito-
metric analysis using LI-COR Odyssey.
(F) Densitometric analysis of western blots to determine absolute abundance of MeCP2 in the different nuclei populations. The positions of molecular weight
markers (kDa) are indicated. Error bars indicate the mean ±SEM. See also Figure S1.
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MeCP2 Affects Neuronal Chromatin Globallythe Mecp2 null brain, suggesting that MeCP2 is broadly distrib-
uted at the locus (Figure 2B). Interestingly, MeCP2 binding over
the Bdnf CGIs is reduced relative to the surrounding regions,
raising the possibility that these active promoters fail to attract
MeCP2 due to their lack of DNA methylation. The intervening
regions are CpG deficient by comparison with CGIs, but limited
bisulfite DNA sequencing confirmed that they are largely methyl-
ated (data not shown). MeCP2 ChIP over the same region in
wild-type liver gave a profile indistinguishable from the Mecp2
null brain, suggesting this profile is a result of the high abundance
in neurons. It was possible that the MeCP2 binding pattern in
the whole brain is an aggregate of a large number of distinct
patterns from individual regions and neuronal subtypes. To
address this, the ChIP was repeated using a specific brainMoleregion: the hippocampus, which represents a relatively restricted
subset of neuronal subtypes. The resulting MeCP2 binding
profile was very similar to that of the wild-type whole brain,
with MeCP2 bound over the entire locus but reduced over the
CGIs (Figure 2B). This finding makes it likely that the ChIP results
represent a consistent pattern across many types of neuron.
A similar approach was used to look at the MeCP2 binding
across a 40 kb region encompassing the Dlx5/6 locus. ChIP
using mature mouse brain gave a reproducibly different pattern
from that previously reported in neonatal mice by Horike et al.,
2005, with MeCP2 bound across the entire region (Figure 2C).
ChIP signal over the same region in Mecp2 null brain was
minimal, verifying the significance of the data. We next chose
to examine MeCP2 occupancy over two housekeeping genes,cular Cell 37, 457–468, February 26, 2010 ª2010 Elsevier Inc. 459
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Figure 2. MeCP2 Shows Widespread Binding across Gene Loci in Mature Brain
(A) Mouse tissues (brain, hippocampus, and liver) were dissected, and ChIP was performed using an antibody against MeCP2. Immunoprecipitated DNA was
analyzed by real-time PCR using a panel of primers. ChIP of the major satellite repeat shows 130-fold enrichment in wild-type brain compared to Mecp2 null
brain, indicating that the antibody is highly specific.
(B) MeCP2 binding profile across 39 kb of the promoter region of Bdnf. The blue vertical lines below the graph indicate CpG sites, with CGIs shaded in light gray.
AlternativeBdnf exons 1 are indicated with dark gray rectangles. The asterisk marks the discrete binding site identified using cultured embryonic cortical neurons
(Chen et al., 2003). ChIP was performed on various tissues as indicated.
(C) MeCP2 ChIP profile across a 40 kb region encompassing theDlx5/6 locus. The asterisk marks the key site identified using brains of 1-day-old mice. Wild-type
whole brain is shown in blue and Mecp2 null whole brain is shown in red.
(D) MeCP2 binding profile across the c-Myc locus in wild-type (blue) and Mecp2 null (red) brains.
(E) MeCP2 binding profile across the Actb locus follows the meCpG density. MeCP2 ChIP was performed on wild-type brain (blue). Total brain genomic DNAwas
subjected to bisulfite sequencing for a continuous run of 262 CpG sites across 9 kb. The methylation density is plotted based on a window size of 650 bp and
step of 50 bp (shown in black). Error bars indicate mean ± SEM.
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MeCP2 Affects Neuronal Chromatin Globallyc-Myc and Actb, which have unmethylated CGIs flanked by
methylated DNA that is comparatively CpG deficient. ChIP
across the c-Myc locus showedMeCP2 bound to themethylated
regions flanking the CGI, but as in the case of Bdnf, MeCP2
binding was depleted across the CGI (Figure 2D). Analysis of
9.5 kb surrounding the Actb locus showed a similar pattern
with higher MeCP2 occupancy across the flanks, but depleted
binding over the CGI (Figure 2E). In order to relate this result to
meCpG density, we performed bisulfite sequencing to unambig-460 Molecular Cell 37, 457–468, February 26, 2010 ª2010 Elsevier Inuously determine modification of all 262 CpG sites across the
Actb region (Figure 2E). The results confirm that the CGI is
DNA methylation free, whereas the flanking region is predomi-
nantly methylated. Due to the variable CpG density, the methyl-
ation level varies dramatically across the locus. Significantly,
the MeCP2 binding profile mirrors the methylation density
through the region. Taken together, the results of these ChIP
experiments fit with the hypothesis that MeCP2 binding tracks
meCpG density.c.
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Figure 3. Brain MeCP2 Binds Selectively to Methylated DNA In Vivo
(A) Whole mouse brains were dissected, and ChIP was performed using antibodies against MeCP2 and acetylated histone H3. Input DNA and immunoprecip-
itated DNA were analyzed by real-time PCR and subjected to bisulfite sequencing. MeCP2 binding profiles across 12 kb of the Xist locus in wild-type male brain
(blue), wild-type female brain (pink), andMecp2 null brain (gray) are shown in (A). The blue vertical lines below the graph indicate CpG sites, with the CGI shaded in
light gray. The transcription start site is indicated with an arrow. The horizontal black line marks the region amplified for bisulfite sequencing.
(B) ChIP was performed on the wild-type female brain for MeCP2 and histone H3 acetylation. Recovered DNA was used for bisulfite sequencing of a region of
the Xist promoter. Each line represents a single clone. Open and filled circles indicate nonmethylated and methylated CpG sites, respectively. Crosses indicate
uncharacterized CpG sites.
(C) MeCP2 ChIP profile across 9 kb of the imprinted Snrpn locus in wild-type brain.
(D) ChIPwas performed on thewild-type brain for MeCP2 and histone H3 acetylation. The resulting DNAwas used for bisulfite sequencing of a region of theSnrpn
promoter. Error bars indicate mean ±SEM.
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MeCP2 Affects Neuronal Chromatin GloballyMeCP2 Tracks the meCpG Density of the Genome
In the light of its high abundance and potentially global binding,
we tested whether MeCP2 acts as a meCpG binding protein in
neurons, or whether it interacts with chromatin regardless of
DNA methylation, as proposed by in vitro chromatin assembly
experiments (Georgel et al., 2003; Nikitina et al., 2007). We
selected genomic regions that occur in both methylated and
nonmethylated states within each cell and asked which of the
two forms bound to MeCP2. First, we characterized binding
over 12 kb of the X-linked Xist locus, comparing male to female
mouse brains (Figure 3A). In male mice, there is a single methyl-
ated copy of the Xist promoter CGI, whereas in females there
are two copies, one methylated and one nonmethylated
(Hendrich et al., 1993). In the male brain, MeCP2 occupies the
entire region, peaking over the densely methylated CGI. The
finding that MeCP2 occupancy drops over nonmethylated
CGIs (Figure 2) but peaks over methylated CGIs implies that
MeCP2 is tracking the density of meCpG.
In females, MeCP2 occupancy flanking the Xist CGI is indis-
tinguishable from the male profile. Over the Xist CGI, however,
MeCP2 binding is reduced by half relative to the male brain
(Figure 3A). This result is consistent with the notion thatMoleMeCP2 is only bound to one of the two Xist CGI alleles in the
female. To test this more rigorously, we combined the ChIP
protocol with bisulfite sequencing to determine the methylation
status of the immunoprecipitated DNA. Input DNA from
female brain gave approximately equal numbers of non-
methylated and methylated clones, as expected, confirming
unbiased PCR amplification (Figure 3B). As a control, we bisul-
fite sequenced Xist DNA immunoprecipitated by an antibody
against acetylated histone H3. This histone mark is specific for
the active Xist allele and duly recovered the nonmethylated
allele in 97% of clones (n = 39 clones). Following ChIP with
anti-MeCP2 antibody, however, 88% of the recovered clones
were methylated (n = 58 clones). A similar result was obtained
by analyzing 9 kb of the imprinted Snrpn locus, which has
a paternal unmethylated allele and a maternal methylated
allele (Sutcliffe et al., 1994). MeCP2 is bound through the
entire region, peaking over the imprinted CGI (Figure 3C). Using
the ChIP-bisulfite protocol, the input DNA gave approximately
equal numbers of nonmethylated and methylated clones
(Figure 3D). As before, acetylated histone H3 ChIP recovered
100% nonmethylated clones (n = 23), whereas 89% of the
clones obtained by MeCP2 ChIP were methylated (n = 19).cular Cell 37, 457–468, February 26, 2010 ª2010 Elsevier Inc. 461
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Figure 4. High-Throughput Sequencing of Immunoprecipitated Chromatin Shows MeCP2 Globally Distributed and Tracking the meCpG
Density
(A) Profiles of MeCP2-bound sequences (blue), CpG density (red), and parallel sequencing from methyl-CpG (meCpG)-rich sequences (green) were analyzed
using a sliding window (5 kb window; 1 kb step). A 52 Mb region of chromosome 5 is shown. The vertical axis represents sequencing hits or number of CpGs
per window.
(B) The genome was scanned using a 500 bp window (100 bp step) and the number of MeCP2 hits per window plotted against the number of CpGs per window.
Box plots are shown with the horizontal line indicating the median and the surrounding box showing the interquartile range. The width of the box is proportional to
the fraction of the genome that corresponds with that CpGdensity. Themajority of CGIs contain greater than 5CpG sites/100 bp as indicated by red line, whereas
the bulk genome has a lower CpG density.
(C) Methylated CGIs were identified by meCpG affinity chromatography. The surrounding 5 kb of genomic DNA was analyzed for MeCP2 binding using a 500 bp
window (100 bp step). Results are presented as for (B). See Figure S2.
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MeCP2 Affects Neuronal Chromatin GloballyWe conclude that MeCP2 preferentially binds to the methylated
allele in each case.
High-Throughput Sequencing Confirms Genome-wide
Binding
Analysis of candidate loci across 150 kb of the mouse brain
genome suggests that MeCP2 is widely distributed. To view
MeCP2 occupancy genome-wide, we performed high-through-
put DNA sequencing of total MeCP2-bound chromatin. In all,
2.9 3 109 bases were sequenced, of which 1.3 3 109 were
uniquely mappable. Despite relatively extensive sequencing,
clear peaks were not identified. Instead, sequencing reads
were dispersed throughout the genome, covering 56% of the
mouse genome (2.5 3 109 bp, of which 1.8 3 109 is repeat
masked). This result fits with our analysis of candidate regions
by ChIP-PCR. Since MeCP2 binding is genome-wide, it would
be necessary to sequence the entire genome several-fold to
obtain a comprehensive high-resolution profile. With 56%
genome coverage, however, we were able to robustly test for
a relationship with DNA methylation by comparing the profile of
the CpG sequence in a sliding 5 kb window with that of MeCP2.462 Molecular Cell 37, 457–468, February 26, 2010 ª2010 Elsevier InThe match was striking (Figure 4A), suggesting that MeCP2
binding coincides with this dinucleotide sequence, which is
70% methylated in brain DNA (Ehrlich et al., 1982). As a more
direct test, we determined the distribution of meCpG by fraction-
ating whole genomic DNA based on its affinity for an immobilized
meCpG-binding domain (Cross et al., 1994; Illingworth et al.,
2008). Retained sequences were analyzed by high-throughput
sequencing. An earlier comparison between this method of
meCpG mapping and use of an anti-meC antibody (MeDIP)
indicated that both are equally effective at measuring meCpG
density (Zhang et al., 2006). We conclude that in vivo-bound
MeCP2 mirrors meCpG over long regions of chromosomal
DNA (Figure 4A).
In a second test for the relationship between MeCP2 binding
and meCpG, we asked whether the depression of MeCP2
binding seen at nonmethylated CGIs associated with the
c-Myc, Dlx5/6, Actb, and Bdnf loci applied genome-wide. We
binned the mouse genome sequence according to CpG density
in 500 bpwindows and determined the level of MeCP2 binding in
each bin. The results (Figure 4B) show that MeCP2 binding
initially increases with base composition, as predicted byc.
Molecular Cell
MeCP2 Affects Neuronal Chromatin GloballyFigure 4A, but drops steeply at densities above 25 CpGs per
500 bp. This density predominantly reflects nonmethylated
CGIs (Figure S2). Third, we examined the binding of MeCP2
to methylated CGIs, as analysis of the Xist and Snrpn loci
suggested increased binding (Figure 3). The results show
a peak of MeCP2 binding centered over methylated CGIs
(Figure 4C). These findings match closely the predictions based
on candidate regions of the genome (Figure 2) and therefore
reinforce the conclusion that MeCP2 tracks DNA methylation
genome-wide.
MeCP2 Globally Alters the Chromatin State
The high abundance of MeCP2 in neurons suggests that it may
influence chromatin structure globally. It was previously reported
that in theMecp2mutantmouse brain, levels of histone H3Ac are
elevated (Shahbazian et al., 2002). As approximately 89% of
MeCP2 is in the neurons, we hypothesized that any differences
in chromatin state between wild-type and Mecp2 null brain
would be restricted to the neurons but be absent from glia. To
test this, we compared H3Ac levels in unsorted nuclei with puri-
fied neuronal and glial nuclei by western blotting (Figure 5A).
Unsorted Mecp2 null brain nuclei displayed a 1.5-fold increase
in H3Ac compared to wild-type. This difference increased signif-
icantly to 2.6-fold in sorted neuronal nuclei (Kolmogorov-
Smirnov [KS] test p % 0.01), whereas glial nuclei consistently
showed no significant increase in H3Ac (0.9-fold decrease).
We conclude that the small elevation of H3Ac seen in whole brain
is entirely due to neurons where MeCP2 is highly abundant. Our
findings do not corroborate a recent report that histone H3Ac is
increased in Mecp2 null glia (Ballas et al., 2009).
Widespread chromosome binding by MeCP2 might be ex-
pected to modulate chromatin structure globally rather than at
specific sites. We asked whether ChIP using an anti-acetyl H3
antibody could detect alterations across specific chromatin
domains in the MeCP2-deficient brain. Due to low recovery of
neuronal nuclei via FACS, whole brain was used, although this
probably leads to an underestimate of changes in neuronal
chromatin. Across the 39 kb Bdnf region, H3Ac peaked over
the active promoter CGI regions in both wild-type and null
(Figure 5B), but was low in flanking regions. Comparing wild-
type and mutant brain, levels of immunoprecipitated DNA
in the mutant were elevated by 2-fold relative to input throughout
the region (KS test p < 0.004). Interestingly, the magnitude of the
effect mirrored the pattern of MeCP2 binding (Figure 5B), being
lowest where MeCP2 binds least (the CGIs) and highest where
most MeCP2 is relatively concentrated. This is compatible with
a simple causal relationship between binding of MeCP2 and
levels of histone deacetylation. A 1.4-fold elevation in histone
acetylation was also seen in regions of the male Xist locus flank-
ing the CGI (Figure S3) (KS test p = 0.03). This difference was
notably absent over the Xist CGI itself, implying that repression
of histone acetylation at this DNA promoter sequence is not
solely dependent on MeCP2. Altogether, we examined 100 loci
covering 90 kb of genomic DNA by quantitative PCR and found
an average 1.4-fold elevation in H3Ac (KS test p < 0.002). These
data indicate that the global chromosomal association ofMeCP2
imposes a reduction in histone acetylation levels across the
genome (Figure 5C).MoleHistone H1 is present in most cell types at an approximate
stoichiometry of one molecule per nucleosome (Woodcock
et al., 2006), but uniquely, in neurons, this is reduced to one
molecule every two nucleosomes (Allan et al., 1984; Pearson
et al., 1984). Chromatin reconstitution experiments showed that
MeCP2 can compete with histone H1 for binding to methylated
chromatin andmay function as a substitute linker histone (Ishiba-
shi et al., 2008; Nan et al., 1997). As MeCP2 occurs at approxi-
mately onemolecule per two nucleosomes in neurons, we asked
whether the abundance of histone H1 was affected by MeCP2
depletion. Using FACS-purified neuronal nuclei, we found that
histone H1 is elevated 2-fold in the Mecp2 null compared to
the wild-type (Figure 5D) (KS test p < 0.05). No difference was
seen in unsorted nuclei from wild-type and mutant whole brain,
suggesting that this effect is specific to neurons where MeCP2
is highly abundant. The level of histone H1 present in MeCP2-
deficient neurons appears to be close to onemolecule per nucle-
osome, as seen in other cell types, suggesting that the reduced
level in neurons may reflect substitution of H1 by MeCP2.
MeCP2 Suppresses Spurious Transcription
of Repetitive Elements
Our results implicate MeCP2 as a global regulator of neuronal
chromatin structure. A possible outcome of MeCP2 depletion
is that increased histone acetylation could lead to inappropriate
transcription from the bulk genome, including dispersed repeti-
tive elements. To test this possibility, we studied expression of
L1 retrotransposons, intracisternal A particles, and tandem
repetitive units of the mouse major satellite, which are methyl-
ated and bound by MeCP2 (Figure S4A). RNA was extracted
from the whole brain, and RT-PCR was used to determine the
expression levels of these elements. No differencewas observed
between wild-type and Mecp2 null brain (Figure S4B). We
considered, however, that spurious transcripts might be
degraded by the exosome and therefore not survive as stable
components of cytoplasmic RNA. To reduce the opportunities
for transcript degradation, RNA was extracted from isolated
nuclei and analyzed by RT-PCR. The same repetitive regions
now showed significantly increased levels of expression in
the Mecp2 null brain compared to the wild-type (Figure 6A).
In contrast, no differences in the expression levels of Actb,
c-Myc, or tyrosine hydroxylase mRNAs were observed (Fig-
ure 6A). On average, repetitive regions showed 1.6-fold overex-
pression in the Mecp2 null brain (four biological replicates; KS
test p < 0.0002), whereas the expression of these bona fide
genes was unaffected (Figures 6B and S4D). These results do
not preclude the possibility that some genes show changes in
the Mecp2 null brain. They argue, however, that one conse-
quence of MeCP2-deficiency in neurons is an increase in tran-
scriptional noise. This effect was not seen in embryonic brains
from E18.5 mice (Figure S4C), suggesting that increased tran-
scriptional noise is confined to the mature brain where MeCP2
is abundant enough to impact the whole genome.
DISCUSSION
Mouse models and human neurological disorders suggest that
appropriate levels of MeCP2 are essential for its proper function,cular Cell 37, 457–468, February 26, 2010 ª2010 Elsevier Inc. 463
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Figure 5. MeCP2DeficiencyAffects theGlobalChromatinStatebyElevatingLevelsofHistoneH3Acetylation (H3Ac) and theLinkerHistoneH1
(A) H3Ac levels were determined by quantitative western blotting of unsorted brain nuclei and FACS-purified nuclei from both wild-type andMecp2 null brain. The
western blot shows H3Ac levels and NeuN (as a loading control) in the purified neuronal nuclei. The graph indicates densitometric analysis of H3Ac levels in the
different nuclei populations, normalized for differences in loading. The horizontal line represents no change between wild-type and Mecp2 null.
(B) The upper graph shows the H3Ac profile across the promoter region of theBdnf locus in wild-type (blue) andMecp2 null (red) brains. The lower graph indicates
the H3Ac fold difference between wild-type and Mecp2 null brain (grey); the MeCP2 ChIP profile is also shown (black). The blue vertical lines below the graph
indicate CpG sites, with the CGI shaded in light gray. The gene structure is indicated by dark gray rectangles below. These data represent the average of three
independent experiments.
(C) Box plot showing all H3Ac ChIP results for wild-type and Mecp2 null brain (n = 100).
(D) Quantitative western blotting for histone H1 and NeuN (as a loading control) using FACS-purified neuronal nuclei from wild-type and Mecp2 null mice. The
graph indicates densitometric analysis of H1 levels in the different nuclei populations. Error bars indicate mean ±SEM, and the KS test was used to determine
statistical significance. See also Figure S3.
Molecular Cell
MeCP2 Affects Neuronal Chromatin Globally
464 Molecular Cell 37, 457–468, February 26, 2010 ª2010 Elsevier Inc.
00.5
1
1.5
2
L1Retro Maj Sat IAP Tyr
Hydrox
c-Myc Actb
nu
ll 
/ w
ild
-ty
pe
0
0.5
1
1.5
Repeats Genes
nu
ll 
/  
w
ild
-ty
pe
Repeats Genes
B
A p < 0.002
p < 0.03
p < 0.01
p < 0.0001
Figure 6. MeCP2 Suppresses Transcription from Repetitive
Elements Distributed Throughout the Genome
(A) Nuclei were isolated from wild-type and Mecp2 null brains. RNA was
extracted and cDNA was prepared with and without reverse transcriptase.
Quantitative PCR was used to determine the expression levels of repetitive
regions and genic regions. The data were normalized to GAPDH and shown
as a ratio between Mecp2 null and wild-type nuclei. The horizontal line repre-
sents no change between wild-type and Mecp2 null mice.
(B) Shows the pooled data, grouping repetitive regions and genic regions.
Error bars indicate mean ±SEM. The KS test was used to determine statistical
significance. See Figure S4.
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MeCP2 Affects Neuronal Chromatin Globallyas both deficiency and mild overexpression result in a neurolog-
ical phenotype (Collins et al., 2004; Guy et al., 2001). Our data
establish MeCP2 as one of the most abundant nuclear proteins
in mature neurons. With an average density of one molecule
every two nucleosomes, there is enough to bind approximately
half of all meCpG sites in the diploid neuronal genome. ChIP
analysis of candidate regions and high-throughput sequencing
confirm that MeCP2 is globally bound and tracks the density of
meCpG in the genome. As for all ChIP analyses, it is possible
that there are transient interactions that are not captured using
formaldehyde crosslinking (Schmiedeberg et al., 2009), and we
may therefore be selectively visualizing stable MeCP2-DNA
interactions.
Our evidence supports earlier contentions that the large
number of potential binding sites fits with a global regulatory
role (Nan et al., 1997). Although provisional identification of
MeCP2 ‘‘target genes’’ has been supported by MeCP2-ChIP
near specific promoters, it is now apparent that most regions
of the genome, including repetitive sequences and intergenic
DNA, are associated with MeCP2 in neurons. The notion that
MeCP2 resembles a transcription factor by being targeted to
a specific subset of genes appears to be incorrect.MoleIn line with its high abundance, MeCP2 impacts the chro-
matin state globally. Histone H1 is atypically low in neurons,
being sufficient only to bind half of all neuronal nucleosomes,
whereas in other cell types the stoichiometry is almost one-
to-one (Allan et al., 1984; Pearson et al., 1984). We found
that when MeCP2 is absent, the amount of neuronal H1
doubles, bringing it to the level typical of most cell types.
There was no comparable effect in glia, where the density of
chromosome-bound MeCP2 is much lower. MeCP2 can
compete with H1 for binding to chromatin containing methyl-
ated DNA in vitro (Nan et al., 1997). Further in vitro studies
have suggested that MeCP2 may function in a manner analo-
gous to a linker histone, as it can bind to entry-exit sites on
nucleosomes and promote the formation of higher order struc-
tures (Ishibashi et al., 2008; Nikitina et al., 2007). It is tempting
to propose that competition for chromatin binding sites
between neuronal MeCP2 and H1 displaces the linker histone
from half of its potential sites, leading to a reduction in the
requirement for H1. In the Mecp2 null brain, where this compe-
tition does not occur, H1 is apparently restored to its conven-
tional nucleosomal stoichiometry of 1:1 and may functionally
compensate in part for MeCP2 deficiency. Further work is
needed to clarify the role of MeCP2 as a putative alternative
linker histone.
Elevated histone acetylation in MeCP2-deficient whole-brain
samples has been reported previously (Shahbazian et al.,
2002). By sorting neuronal from glial nuclei, we show that this
difference is entirely due to a large change in neurons, with no
corresponding alteration detectable in glia. Using ChIP, we
show that this increase is distributed throughout the genome
rather than at distinct sites. Early evidence suggested that
MeCP2 can recruit the HDAC-containing complexes (Nan
et al., 1998). A plausible model, therefore, is that MeCP2 attracts
corepressors throughout the genome, which depress histone
acetylation according to the local density of meCpG. The finding
that the ratio of mutant to wild-type H3Ac matches the density
profile of MeCP2 (Figure 5B) provides support for this conten-
tion. We propose that these global effects of MeCP2 deficiency
on both H1 abundance and histone acetylation are seen exclu-
sively in neurons because only in these cells is MeCP2 suffi-
ciently abundant to coat the genome. In other cell types, the
low density of MeCP2 occupancy is insufficient to impact bulk
chromatin.
Studies with in vitro reconstituted chromatin have suggested
that MeCP2 might play a structural role in chromatin regardless
of DNA methylation (Georgel et al., 2003). Against this hypoth-
esis, other studies have showed MeCP2 preferentially binds
methylated DNA (Gregory et al., 2001; Nan et al., 1996). We
establish that even in neurons, where MeCP2 abundance is
equivalent to that of histone H1, DNA methylation dependence
still holds. These in vivo data reinforce the view that MeCP2
binding depends upon the methylation status of chromosomal
DNA. This dependence may account for the remarkable
reversibility of severe neurological symptoms in mice when
MeCP2 is restored following development under MeCP2-defi-
cient conditions (Guy et al., 2007). If, as seems likely, DNAmeth-
ylation patterns are laid down normally in the absence of
MeCP2, then the restored protein is expected to distributecular Cell 37, 457–468, February 26, 2010 ª2010 Elsevier Inc. 465
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function.
The global distribution of MeCP2 casts light on gene expres-
sion studies, which initially detected few significant changes
between Mecp2 null and wild-type brain (Jordan et al., 2007)
but more recently have reported large numbers of subtle
alterations comprising both increases and decreases in gene
expression (Chahrour et al., 2008). Where a transcriptional regu-
lator affects a restricted number of genes, coherent expression
changes at those genes are expected when the protein is defi-
cient. If, however, a large proportion of all genes are affected,
it is more difficult to predict how deficiency will impact expres-
sion. The HDAC inhibitor trichostatin A, for example, causes
dramatic hyperacetylation of histones, but despite the clear
association between histone hyperacetylation and transcrip-
tional activity, the drug usually causes equal numbers of genes
to be up- and downregulated (Peart et al., 2005). A potential
explanation is that the nucleus contains limiting supplies of
transcriptional machinery, so that increased expression at
some loci must be matched by decreases at others, even if all
genes are potentially activated by hyperacetylation. By analogy,
the high abundance of MeCP2 may mean that many genes are
potentially affected, but analysis of stable gene expression
patterns following long-term absence of MeCP2 may not accu-
rately reflect these effects.
Our hypothesis that high levels of MeCP2 affect global chro-
matin structure is supported by elevated transcriptional noise
from repetitive elements in nuclei of the Mecp2 null brain. This
effect is absent in embryonic brains, suggesting that the
abundance of MeCP2 is key. Expression of bona fide genes,
on the other hand, was not elevated, which may mean either
that most transcription rates are little changed or that posttran-
scriptional controls are able to compensate. We suggest that
globally bound MeCP2 dampens transcription in a genome-
wide manner by recruiting HDAC activity and acting as a linker
histone. Why might neurons have evolved a requirement for
MeCP2 as a genome-wide transcriptional dampener, whereas
other somatic tissues have not? One possibility is that the
neurons are particularly sensitive to the levels of transcriptional
noise from the bulk genome and therefore have a special need
for MeCP2 to quench this. Another potential explanation is that
neuronal plasticity and homeostasis depend upon the specific
ability of MeCP2 to respond dynamically to activity. Neuronal
firing leads to a burst of synaptic protein synthesis and nuclear
transcription, which is required for development of synaptic
systems (Bading, 2000). MeCP2 undergoes site-specific phos-
phorylation following synaptic firing, which is reported to alter
its affinity for DNA and its nuclear distribution (Chen et al.,
2003; Zhou et al., 2006). We speculate that phosphorylation
may transiently relieve the genome-wide repressive chromatin
structure maintained by MeCP2 and thereby facilitate appro-
priate gene expression. Further reports of posttranslational
modifications of MeCP2 (Tao et al., 2009) raise the possibility
that MeCP2 is a signaling hub within neurons and as such may
play a crucial role in neuronal maintenance. Recognition of
MeCP2 as a global chromatin regulator that is responsive to
neuronal activity promises to shed light on the molecular basis
of Rett syndrome.466 Molecular Cell 37, 457–468, February 26, 2010 ª2010 Elsevier InEXPERIMENTAL PROCEDURES
Mouse Models
C57BL/6Mecp2tm1.1Birdmicewere used,withwild-type littermates as controls.
Unless otherwise stated, allmicewere 6–8weeks of age.Micewere euthanized
by CO2 asphyxiation. Tissues were dissected and either frozen in nitrogen for
ChIP or used directly for nuclear preparation.
Nuclei Preparation
Mouse brain nuclei were isolated as previously described (Klose and Bird,
2004). Recovered nuclei were resuspended in 1 3 PBS supplemented with
20% glycerol, 10 mM sodium butyrate, and complete protease inhibitors
(Roche; Indianapolis, IN); frozen in liquid nitrogen; and stored at 80C.
Serial dilutions of nuclei were counted using a hemocytometer to determine
concentration. Nuclei were lysed in Laemmli buffer and used directly for gel
electrophoresis.
Fluorescence-Activated Cell Sorting
Detailed protocols are available in the Supplemental Information.
Gel Electrophoresis and Western Blotting
Proteins were resolved by SDS-PAGE and transferred to PVDF membrane.
Visualization of reactive proteins was performed by enhanced chemilumines-
cence and quantitative infrared imaging (LI-COR Odyssey, LI-COR Biosci-
ences; Lincoln, NE). Intensity of protein bands was quantified using NIH
ImageJ and LI-COR software. Details of recombinant proteins are in the
Supplemental Information.
ChIP and Solexa Analysis
Detailed protocols are available in the Supplemental Information.
Bisulfite Sequencing
Bisulfite treatment of DNA and sequencing was carried out as previously
described (Illingworth et al., 2008).
Expression Analysis
For whole-cell expression analysis, RNA was extracted using TriReagent
(Sigma-Aldrich; St. Louis) from whole brain disrupted using a polytron (Janke
and Kunkel; Wilmington, NC). For nuclear expression analysis, equal numbers
of nuclei were lysed in extraction buffer (30 mM Tris-HCl [pH 7.5], 300 mM
NaCl, 10 mM EDTA, 1% SDS, 0.5 mg/ml Proteinase K, 0.2 U/ml RNAsin) for
45 min at 37C. Subsequently, the RNA was extracted using acid phenol
and then precipitated with ethanol. After DNaseI treatment (Ambion DNA-
free; Foster City, CA), cDNA was transcribed using Moloney murine leukemia
virus reverse transcriptase (Promega; Madison, WI). Real-time PCR was
carried out using Quantace SensiMix Plus (primer sequences are available
on request).
ACCESSION NUMBERS
High-throughput sequencing data have been deposited in the Gene Expres-
sion Omnibus (GEO) under the accession number GSE19786.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at doi:10.1016/
j.molcel.2010.01.030.
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